The immune system possesses legions of T cells that, if they were primed, could hunt down and destroy tumors. Now, a UC San Francisco team has invented a way to do this by combining immune cells that are grown in the lab with samples from a patient’s tumor.
Like giving a scent to a hound dog, it shows the immune system how to go after the cancer.
The T cells first need to be taught by dendritic cells, which are rare immune cells that are hard to obtain from cancer patients. The UCSF method gets around this by making dendritic cells from induced pluripotent stem cells (iPSCs), which can be grown in large quantities in the laboratory.
Since typical iPSCs would be rejected by the immune system, the scientists first strip them of identifying information, then prompt them to mature into dendritic cells. Finally, they “dress” the dendritic cells with tiny membrane bubbles made from tumor cells. These give the dendritic cells many different signs of the cancer to show to T cells.
In laboratory experiments using tumor samples and T cells from patients with leukemia and ovarian cancer, the dressed dendritic cells were able to train the T cells to kill tumors from the same patient. The treatment also slowed tumor growth in a mouse model. The findings appear in Cell Stem Cell on Aug. 25 .
“For cell-based therapies to work, they need to avoid immune rejection by the body, and they need to target the cancer and not healthy tissue,” said Robert Blelloch , MD, PhD, a professor in the Department of Urology at UCSF and senior author of the paper. “Our combination of iPSC-derived dendritic cells with patients’ own tumor signature checks both boxes and we’re very hopeful it could work in the clinic.”
Instead of trying to identify the right cancer targets one by one, the researchers broke apart the membranes of tumor cells and let them form into tiny bubbles. These bubbles merged with the dendritic cells, coating them with tiny pieces of the patient’s tumor.
This both made the dendritic cells look more like the patient’s own cells and carried a wide range of cancer targets. All that information could make it harder for a tumor to escape just by shedding a single target, a problem that can limit other immunotherapies.
Home-schooling the immune system
Once the scientists showed that the tumor membrane had integrated into the dendritic cells, they tested whether the cells could prompt T cells to find and fight cancer.
The dendritic cells did more than carry pieces of the tumor. They also produced the specific instructions that the T cells needed to recognize the tumor pieces as a threat — and the scientists were able to amplify those “attack” instructions, leading to an even stronger T cell response.
The approach worked in petri dishes using tumor samples and T cells from the same patients, and it slowed the growth of human cancer cells in mice.
For Blelloch, one potential use is easy to imagine. Surgery can remove prostate tumors, for example, but some patients still face a high risk that the cancer will return.
“After surgery, we have all the tumor tissue needed to make a bespoke therapy for that patient’s cancer,” Blelloch said. “We could dress artificial dendritic cells with pieces of the biopsy, place them back in the patient to educate T cells, and then the T cells could go kill any remaining cancer cells in the body, removing the risk of the tumor returning.”
Authors: Other UCSF authors are Huaigeng Xu, MD, PhD; Chisato Kamei, MD; Deniz Goekbuget, PhD; Jacob Du; Mercedes Barrero, PhD; Li Wang, PhD; Jason Mark Soriano; Serena S. Kwek, PhD; Lawrence Fong, MD; and Karin M.L. Gaensler, MD. For all authors, see the paper.
Funding: This work is supported by the National Institutes of Health (U01CA244452), the California Institute of Regenerative Medicine (DISC0-13806, EDUC4- 12812), a NIH Cancer Moonshot Award, a Sandler Program for Breakthrough Biomedical Research New Frontiers Award, and Benioff Initiative for Prostate Cancer Research.
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health , which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu or see our Fact Sheet .
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf
Cell Stem Cell